Skip to content

Study · Observational study · n = 118 · 2017

4 results

Methylene Blue for Vasoplegic Syndrome After Cardiac Operation: Early Administration Improves Survival.

Mehaffey JH, Johnston LE, Hawkins RB, Charles EJ, Yarboro L, Kern JA, Ailawadi G, Kron IL, Ghanta RK

The Annals of thoracic surgery24 May 2017Cited by 80 (Europe PMC)

PMID28551045 (opens in a new tab)PMCIDPMC5523819 (opens in a new tab)DOI10.1016/j.athoracsur.2017.02.057 (opens in a new tab)PepBankPUB-28551045
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studySafety outcome

    In post-bypass vasoplegia, early methylene blue administration was linked to lower operative mortality than late administration.

    In plain wordsIn post-bypass vasoplegia, early methylene blue administration was linked to fewer deaths than late administration.

    Peptide
    Methylene blue
    Outcome
    DecreaseOperative mortality by timing
    Study

    n = 118

    Comparator
    Late ICU administration of MB
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Measurements

    Operative mortality
    10.4%
    early administration
    Operative mortality
    28.6%
    late administration

    Source sentences

    Summary
    Early (operating room, 40.7%) versus late (intensive care unit, 59.3%) administration of MB was associated with significantly reduced operative mortality rate (10.4% versus 28.6%, p = 0.018) and risk-adjusted major adverse events (odd ratio 0.35, p = 0.037).
    3 context sentences
    Summary · context
    All patients that underwent cardiopulmonary bypass at our institution (Jan 1, 2011 to Jun 30, 2016) were identified through our Society of Thoracic Surgery database.
    Summary · context
    Pharmacy records identified patients receiving MB within 72 hours of cardiopulmonary bypass.
    Summary · context
    A total of 118 cardiopulmonary bypass patients (3.3%) received MB for vasoplegic syndrome.
  2. 02HumanObservational studySafety outcome

    In post-bypass vasoplegia, early methylene blue administration was linked to fewer risk-adjusted major adverse events than late administration.

    In plain wordsIn post-bypass vasoplegia, early methylene blue administration was linked to fewer major adverse events than late administration.

    Peptide
    Methylene blue
    Outcome
    DecreaseRisk-adjusted major adverse events by timing
    Study

    n = 118

    Comparator
    Late ICU administration of MB
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Measurements

    Odds ratio
    0.35
    early versus late administration

    Source sentences

    Summary
    Early (operating room, 40.7%) versus late (intensive care unit, 59.3%) administration of MB was associated with significantly reduced operative mortality rate (10.4% versus 28.6%, p = 0.018) and risk-adjusted major adverse events (odd ratio 0.35, p = 0.037).
    3 context sentences
    Summary · context
    All patients that underwent cardiopulmonary bypass at our institution (Jan 1, 2011 to Jun 30, 2016) were identified through our Society of Thoracic Surgery database.
    Summary · context
    Pharmacy records identified patients receiving MB within 72 hours of cardiopulmonary bypass.
    Summary · context
    A total of 118 cardiopulmonary bypass patients (3.3%) received MB for vasoplegic syndrome.
  3. 03HumanObservational studySafety outcome

    After cardiopulmonary bypass, methylene blue recipients had higher postoperative complication rates than other patients, except atrial fibrillation.

    In plain wordsAfter cardiopulmonary bypass, methylene blue recipients had higher postoperative complication rates than other patients, except atrial fibrillation.

    Peptide
    Methylene blue
    Outcome
    IncreasePostoperative complications
    Study

    n: not reported in source

    Comparator
    Patients not receiving MB
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MB patients had significantly higher rates of postoperative complications, except atrial fibrillation.
    3 context sentences
    Summary · context
    All patients that underwent cardiopulmonary bypass at our institution (Jan 1, 2011 to Jun 30, 2016) were identified through our Society of Thoracic Surgery database.
    Summary · context
    Pharmacy records identified patients receiving MB within 72 hours of cardiopulmonary bypass.
    Summary · context
    A total of 118 cardiopulmonary bypass patients (3.3%) received MB for vasoplegic syndrome.
  4. 04HumanObservational studySafety outcome

    After cardiopulmonary bypass, atrial fibrillation was an exception to higher postoperative complication rates in methylene blue recipients.

    In plain wordsAfter cardiopulmonary bypass, atrial fibrillation was an exception to higher complication rates in methylene blue recipients.

    Peptide
    Methylene blue
    Outcome
    Direction not reportedAtrial fibrillation
    Study

    n: not reported in source

    Comparator
    Patients not receiving MB
    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MB patients had significantly higher rates of postoperative complications, except atrial fibrillation.
    3 context sentences
    Summary · context
    All patients that underwent cardiopulmonary bypass at our institution (Jan 1, 2011 to Jun 30, 2016) were identified through our Society of Thoracic Surgery database.
    Summary · context
    Pharmacy records identified patients receiving MB within 72 hours of cardiopulmonary bypass.
    Summary · context
    A total of 118 cardiopulmonary bypass patients (3.3%) received MB for vasoplegic syndrome.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.